Patent classifications
A61K35/18
BLOOD PREPARATION USEFUL FOR WOUND HEALING AND TISSUE REGENERATION
The invention provides a blood preparation consisting of platelet- and lymphocyte-enriched plasma, the use thereof for wound healing and body tissue regeneration, pharmaceutical and cosmetic compositions containing it and a method for its preparation.
BLOOD PREPARATION USEFUL FOR WOUND HEALING AND TISSUE REGENERATION
The invention provides a blood preparation consisting of platelet- and lymphocyte-enriched plasma, the use thereof for wound healing and body tissue regeneration, pharmaceutical and cosmetic compositions containing it and a method for its preparation.
COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
RED BLOOD CELL-DERIVED VESICLE
The invention relates to red blood cell-derived vesicles comprising encapsulated active agents, their use in therapy and methods of production thereof.
COMPOSITIONS AND METHODS RELATING TO ERYTHROCYTES WITH ADHERED PARTICLES
Provided herein are erythrocytes with polymeric particles (i.e., ‘backpacks’) adhered that provide delivery of payload therapeutic agents to subjects administered these cells.
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.
Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.